Linked Life Data

9732411

Source:http://linkedlifedata.com/resource/pubmed/id/9732411

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9732411rdf:typepubmed:Citationlld:pubmed
pubmed-article:9732411lifeskim:mentionsumls-concept:C0225828lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C0030274lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C1955862lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C0806140lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:9732411lifeskim:mentionsumls-concept:C0757822lld:lifeskim
pubmed-article:9732411pubmed:issue3lld:pubmed
pubmed-article:9732411pubmed:dateCreated1998-10-8lld:pubmed
pubmed-article:9732411pubmed:abstractTextThe novel sulfonylthiourea HMR 1883 was investigated in in vitro systems. The rilmakalim-induced shortening of the APD90 in guinea pig right papillary muscle at pHo = 6.0 was antagonized half-maximally by glibenclamide and HMR 1883 with 0.14 microM and 0. 6 microM, respectively. Hypoxia-induced shortening of the APD90 was significantly attenuated by the sulfonylureas when applied 60 min after induction of hypoxia. In isolated guinea pig ventricular myocytes the APD90 as well as the whole-cell current was measured with the patch-clamp technique. The rilmakalim-induced shortening of the APD90 was half-maximally antagonized by glibenclamide and HMR 1883 with 10 nM and 0.4 microM, respectively (pHo = 6.5). The rilmakalim-induced whole-cell current (at 0 mV clamp-potential) was inhibited by glibenclamide and HMR 1883 half-maximally with 20 nM and 0.8 microM, respectively (pHo = 7.4). In isolated perfused guinea pig hearts, the coronary flow (CF) was increased by perfusion with hypoxic solution (20% O2). Whereas 1 microM glibenclamide completely inhibited the hypoxia-induced increase in CF, 10 microM HMR 1883 reduced it by only 18%. Pancreatic effects were investigated in rat insulinoma cells (RINm5F), which were hyperpolarized with 100 microM diazoxide. Addition of glibenclamide or HMR 1883 depolarized the cell potential half-maximally with concentrations of 9 nM and approximately 20 microM, respectively. In conclusion, the sulfonylthiourea HMR 1883 blocks KATPs in cardiac muscle cells with 10-50 fold higher potency than in pancreatic beta-cells and has little effect on the coronary vascular system. Therefore, HMR 1883 has pharmacological selectivity for cardiac myocytes and thereby may be a promising substance for the prevention of ischemia-induced ventricular fibrillation.lld:pubmed
pubmed-article:9732411pubmed:languageenglld:pubmed
pubmed-article:9732411pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:citationSubsetIMlld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9732411pubmed:statusMEDLINElld:pubmed
pubmed-article:9732411pubmed:monthSeplld:pubmed
pubmed-article:9732411pubmed:issn0022-3565lld:pubmed
pubmed-article:9732411pubmed:authorpubmed-author:GögeleinHHlld:pubmed
pubmed-article:9732411pubmed:authorpubmed-author:HartungJJlld:pubmed
pubmed-article:9732411pubmed:authorpubmed-author:SchölkensB...lld:pubmed
pubmed-article:9732411pubmed:authorpubmed-author:EnglertH CHClld:pubmed
pubmed-article:9732411pubmed:issnTypePrintlld:pubmed
pubmed-article:9732411pubmed:volume286lld:pubmed
pubmed-article:9732411pubmed:ownerNLMlld:pubmed
pubmed-article:9732411pubmed:authorsCompleteYlld:pubmed
pubmed-article:9732411pubmed:pagination1453-64lld:pubmed
pubmed-article:9732411pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:meshHeadingpubmed-meshheading:9732411-...lld:pubmed
pubmed-article:9732411pubmed:year1998lld:pubmed
pubmed-article:9732411pubmed:articleTitleHMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part I: effects on cardiomyocytes, coronary flow and pancreatic beta-cells.lld:pubmed
pubmed-article:9732411pubmed:affiliationHoechst Marion Roussel, DG Cardiovascular, H 821, D-65926 Frankfurt/Main, Germany.lld:pubmed
pubmed-article:9732411pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9732411lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9732411lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9732411lld:pubmed